Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.39 |
| ▸ | CTSS | P25774 | 7/20 | 0.35 |
| ▸ | CTSK | P43235 | 7/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908318 | 0.84 | KLK5 (0.44) | CACNA1BCTSSCTSKCTSLCTSB | |
| SCHEMBL16119293 | 0.84 | KLK5 (0.44) | CACNA1BCTSSCTSKCTSLCTSB | |
| SCHEMBL16228157 | 0.84 | KLK5 (0.44) | CACNA1BCTSSCTSKCTSLCTSB | |
| SCHEMBL16228847 | 0.83 | ACE (0.48) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL16119290 | 0.83 | ACE (0.48) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL16119295 | 0.81 | CTSS (0.41) | CTSSCTSKCTSLCTSBAAK1 | |
| SCHEMBL16119115 | 0.81 | ACE (0.41) | CACNA1BCTSSCTSKCTSLCTSB | |
| SCHEMBL8909470 | 0.81 | ALDH1A1 (0.46) | CACNA1BCTSSCTSK | |
| SCHEMBL17483752 | 0.79 | CTSK (0.38) | CACNA1BCTSSCTSKCTSLCTSB | |
| SCHEMBL21066490 | 0.79 | PSMB9 (0.47) | CACNA1BCTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657057-B2 | Dipeptide and tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657057-B2 | Dipeptide and tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160031934-A1 | DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031934-A1 | DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031934-A1 | DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, PEPD, DNPEP | JAK3 1009/4885BTK 2237/4885CACNA1B 4620/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | JAK3 1768/4885BTK 2979/4885CACNA1B 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.